C

CASI Pharmaceuticals Inc
NASDAQ:CASI

Watchlist Manager
CASI Pharmaceuticals Inc
NASDAQ:CASI
Watchlist
Price: 5.75 USD 3.6%
Market Cap: 77.1m USD
Have any thoughts about
CASI Pharmaceuticals Inc?
Write Note

CASI Pharmaceuticals Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CASI Pharmaceuticals Inc
Accounts Payable Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
C
CASI Pharmaceuticals Inc
NASDAQ:CASI
Accounts Payable
$4.4m
CAGR 3-Years
6%
CAGR 5-Years
35%
CAGR 10-Years
27%
Abbvie Inc
NYSE:ABBV
Accounts Payable
$30.5B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accounts Payable
$18.9B
CAGR 3-Years
153%
CAGR 5-Years
80%
CAGR 10-Years
35%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Payable
$3.6B
CAGR 3-Years
205%
CAGR 5-Years
108%
CAGR 10-Years
58%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Payable
$497.3m
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
27%

See Also

What is CASI Pharmaceuticals Inc's Accounts Payable?
Accounts Payable
4.4m USD

Based on the financial report for Dec 31, 2023, CASI Pharmaceuticals Inc's Accounts Payable amounts to 4.4m USD.

What is CASI Pharmaceuticals Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
27%

Over the last year, the Accounts Payable growth was 34%. The average annual Accounts Payable growth rates for CASI Pharmaceuticals Inc have been 6% over the past three years , 35% over the past five years , and 27% over the past ten years .

Back to Top